OTC · BMYMP
Healthcare · Drug Manufacturers - General
$400.00
Down-$540.22 (-57.46%)
Updated Nov 4, 2026, 8:03 AM
SID Score
6.2/10
Composite research score
Smart Money
46/100
Neutral
Price performance · BMYMP
1M range · 0 trading sessions · Daily adjusted prices
BMYMP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BMYMP.
Company
Market Activity
Research & News
BMYMP research
Company profile and research snapshot.
BRISTOL-MYERS SQUIBB $2PR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | Underweight | — |
| Oct 26, 2026 | Piper Sandler | Overweight | — |
| Oct 13, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Oct 7, 2026 | Morgan Stanley | Underweight | — |
No generated briefing is available yet.
SeekingAlpha · Mar 24, 2026
AQRâs Q4 2025 13F: $191B portfolio led by Nvidia plus Apple, Microsoft, Alphabet & Amazon, with selective diversification. See more details here.
Yahoo · Mar 9, 2026
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
Yahoo · Mar 9, 2026
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.
Yahoo · Mar 9, 2026
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Interpretive context generated from the platform’s current data sources.
Bristol-Myers Squibb's convertible preferred series 2 shares (BMYMP) currently trade at $400.00 per share, per SID market data. The security exhibits notably low volatility characteristics, registering a beta of just 0.30, indicating the preferred shares move approximately 70% less than the broader market on a relative basis. Average daily trading volume stands at just 5 shares, according to Massive/Polygon data, reflecting the extremely illiquid nature of this convertible preferred instrument. This limited liquidity is characteristic of legacy preferred securities with small outstanding share counts. The parent company, Bristol-Myers Squibb, carries a total market capitalization of approximately $1.82 trillion across all share classes, positioning it among the largest entities in the Healthcare sector. The low beta and minimal trading activity suggest this instrument primarily attracts buy-and-hold investors seeking income and conversion optionality rather than active traders pursuing short-term price movements.
BMYMP currently reflects a price-to-earnings ratio of 17.28 based on the parent company's underlying earnings, per SID market data. The PEG ratio stands at 0.90, suggesting that when earnings growth is factored into the valuation, the security trades below the commonly referenced fair-value threshold of 1.0. The price-to-book ratio registers at 5.62, according to SEC filings, which is elevated relative to the broader market but consistent with established pharmaceutical companies that carry significant intangible asset value from drug portfolios and intellectual property. The convertible preferred shares offer a dividend yield of 4.84%, providing a meaningful income component for holders. Within the Healthcare sector, this yield exceeds what common equity typically delivers, reflecting the preferred structure's priority in the capital stack. The combination of a sub-1.0 PEG ratio and a nearly 5% dividend yield presents a quantitatively notable profile among healthcare-related securities.
The composite smart money score for BMYMP stands at 46 out of 100, generating a Neutral signal according to SID market data. Breaking down the four subcategories reveals a mixed institutional positioning landscape. Insider activity scores 12.5 out of 25, per SEC Form 4 filings, indicating neither aggressive accumulation nor notable distribution by company executives and directors. Institutional ownership activity registers at 13.0 out of 25, based on 13F institutional filings, reflecting moderate but unremarkable positioning by large fund managers. The dark pool activity score of 8.5 out of 25 is the weakest component, suggesting minimal block trading or off-exchange institutional transactions, which aligns with the security's extremely low average daily volume of just 5 shares. Congressional trading activity scores 12 out of 25, indicating no significant legislative insider positioning. The overall neutral reading across all four subcategories suggests institutional and sophisticated investors are maintaining existing positions without meaningful directional conviction in either direction on this convertible preferred instrument.
No recent earnings data specific to the BMYMP convertible preferred series 2 is currently available in the reporting database. As a preferred equity instrument, BMYMP does not independently report earnings; its fundamental value is derived from the parent company Bristol-Myers Squibb's consolidated financial performance. The current P/E ratio of 17.28, per SID market data, reflects the parent company's trailing earnings applied to this preferred security's price. The PEG ratio of 0.90 implies that consensus forward earnings growth expectations, when available, suggest growth-adjusted valuation sits below parity. The 4.84% dividend yield remains a critical metric for preferred holders, as dividend coverage depends directly on Bristol-Myers Squibb's consolidated cash flow generation and earnings stability. Investors in this instrument typically monitor the parent company's quarterly earnings releases, pipeline developments, and patent expiration timelines to assess ongoing dividend sustainability and conversion value relative to common shares.
Recent Wall Street coverage of Bristol-Myers Squibb reflects a divided outlook among analysts, per SID consensus data. Morgan Stanley maintained an Underweight rating on both October 30 and October 7, 2026, representing the most bearish stance among covering firms. In contrast, Piper Sandler reiterated an Overweight rating on October 26, 2026, according to Wall Street analyst reports, positioning it as the most constructive voice in recent coverage. Wells Fargo maintained an Equal-Weight rating on October 13, 2026, while Cantor Fitzgerald held a Neutral stance as of October 8, 2026. Notably, all four recent rating actions represent reiterations rather than upgrades or downgrades, indicating no analyst shifted directional conviction during this period. The distribution includes one Overweight, two neutral-equivalent ratings, and one Underweight, producing a balanced consensus that aligns with the security's neutral smart money score of 46. This lack of consensus change suggests analysts await additional catalysts before adjusting their positioning on Bristol-Myers Squibb securities.
The latest Smart Investors Daily articles mentioning BMYMP.
